1
|
Hasanreisoglu M, Halim MS, Kesim C, Doan HL, Tran ANT, Nguyen W, Besalti Z, Lajevardi S, Hassan M, Akhavanrezayat A, Ahmed MI, Do DV, Sepah YJ, Nguyen QD. Longitudinal Comparative Analysis of Semi-Automated Aqueous Flare Measurements with Clinical Grading and Visual Outcomes in Uveitic Eyes. Ocul Immunol Inflamm 2023; 31:1819-1824. [PMID: 36170559 PMCID: PMC10870827 DOI: 10.1080/09273948.2022.2123365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 09/05/2022] [Indexed: 10/14/2022]
Abstract
PURPOSE To evaluate the correlation between longitudinal changes in aqueous flare measured by laser flare photometer (LFP), best-corrected visual acuity (BCVA), and clinical grade using both Standardization of Uveitis Nomenclature (SUN) and modified SUN (MSUN) scales uveitis patients. METHODS Patients were classified according to both SUN and MSUN grading scales. LFP measurements were acquired (Kowa FM-700) at each visit. Mean change in LFP was assessed longitudinally, comparing with those in visual acuity, SUN, and MSUN grading scales. RESULTS Mean change in LFP was correlated to those in BCVA (p = .018), SUN scale (p < .001), and MSUN scale (p = .008). Cases within same initial SUN (0 and 1+) and MSUN (0.5+ and 1+) grades and different longitudinal flare prognosis (decreased/unchanged/increased) had significantly different initial LFP values (all p < .05). CONCLUSIONS LFP measurement is beneficial in monitoring inflammatory activity. Cases of identical clinical flare scores with different clinical prognosis may be predicted by LFP.
Collapse
Affiliation(s)
- Murat Hasanreisoglu
- Department of Ophthalmology, Koç University School of Medicine, Istanbul, Turkey
- KUTTAM, Koç University Research Center for Translational Medicine, Istanbul, Turkey
| | - Muhammad Sohail Halim
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
- Department of Ophthalmology, Ocular Imaging Research and Reading Center, Sunnyvale, California, USA
| | - Cem Kesim
- Department of Ophthalmology, Koç University School of Medicine, Istanbul, Turkey
| | - Hien Luong Doan
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
| | - Anh N. T. Tran
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
| | - Will Nguyen
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
| | - Zelal Besalti
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
| | - Sherin Lajevardi
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
| | - Muhammad Hassan
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
| | | | - Mohamed Ibrahim Ahmed
- Department of Ophthalmology, Ocular Imaging Research and Reading Center, Sunnyvale, California, USA
| | - Diana V. Do
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
| | - Yasir J. Sepah
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
| | - Quan Dong Nguyen
- Byers Eye Institute, Stanford University, Palo Alto, California, USA
| |
Collapse
|
2
|
Regenold J, Doan HL, Ghoraba H, Khojasteh H, Jaclyn Hwang JJ, Yavari N, Akhavanrezayat A, Than NTT, Le AHD, Halim MS, Nguyen QD. Evaluation of correlation between Diopsys® NOVA™ fixed-luminance flicker ERG and Diagnosys® Espion 2™ flicker ERG parameters. Doc Ophthalmol 2023:10.1007/s10633-023-09934-x. [PMID: 37219642 DOI: 10.1007/s10633-023-09934-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 04/07/2023] [Indexed: 05/24/2023]
Abstract
PURPOSE Diopsys® NOVA™ is a novel full-field electroretinography (ffERG) device that can make rapid measurements of retinal electrophysiologic function. Diagnosys® Espion 2™ is a clinical gold-standard ERG device. This study aimed to investigate whether light-adapted Diopsys® NOVA™ fixed-luminance flicker ffERG magnitude and implicit time (converted from phase) measurements correlate with light-adapted Diagnosys® Espion 2™ flicker ffERG amplitude and implicit time measurements, respectively. METHODS Twelve patients (22 eyes) with various retinal and uveitic diseases underwent light-adapted Diagnosys® Espion 2™ and Diopsys® NOVA™ fixed-luminance flicker testing. Diopsys® magnitude and implicit time (converted from phase) measurements were compared to Diagnosys® amplitude and implicit time measurements, and a Pearson correlation was used to evaluate any existing correlation. Groups were also compared using generalized estimating equations. Bland-Altman plots were utilized to determine agreement between the comparison groups. RESULTS Age of patients ranged from 14 to 87 years. 58% (n = 7/12) of patients were female. A significant, positive correlation (r = 0.880, P < 0.001) was observed between magnitude (Diopsys®) and amplitude (Diagnosys®) measurements. Amplitude increases by 6.69 µV for each 1 µV increase in Magnitude (p-value < 0.001). A statistically significant, strong positive correlation was observed between Diopsys® implicit time measurements (converted from phase) and Diagnosys® implicit time measurements (r = 0.814, p-value < 0.001). For each 1 ms increase in Diopsys® implicit time, Diagnosys® implicit time increases by 1.13 ms (p-value < 0.001). CONCLUSIONS There is a statistically significant positive correlation between light-adapted Diopsys® NOVA™ fixed-luminance flicker amplitude and Diagnosys® flicker magnitude values. Additionally, there is a statistically significant positive correlation between Diopsys® NOVA™ fixed-luminance flicker implicit time (converted from phase) and Diagnosys® flicker implicit time values. These results imply that the Diopsys® NOVA™ module, which utilizes the nonstandard shortened International Society for Clinical Electrophysiology of Vision (ISCEV) ERG protocol, can produce reliable light-adapted flicker ffERG measurements.
Collapse
Affiliation(s)
- Jonathan Regenold
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
- University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Hien Luong Doan
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
- Pham Ngoc Thach University of Medicine, Saigon, Vietnam
| | - Hashem Ghoraba
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
| | - Hassan Khojasteh
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
- Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Jaclyn Joyce Jaclyn Hwang
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
| | - Negin Yavari
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
| | - Amir Akhavanrezayat
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
| | - Ngoc Trong Tuong Than
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
| | - Anthony Huy Dinh Le
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
- University of Missouri - Kansas City School of Medicine, Kansas City, Missouri, USA
| | - Muhammad Sohail Halim
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA
- Ocular Imaging Research and Reading Center, Sunnyvale, CA, USA
| | - Quan Dong Nguyen
- Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA.
| |
Collapse
|
3
|
Uludag G, Hassan M, Matsumiya W, Pham BH, Chea S, Trong Tuong Than N, Doan HL, Akhavanrezayat A, Halim MS, Do DV, Nguyen QD. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further? Expert Opin Biol Ther 2022; 22:1275-1291. [PMID: 35818801 PMCID: PMC10863998 DOI: 10.1080/14712598.2022.2100694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 07/08/2022] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Diabetic retinopathy (DR) is one of the most frequent microvascular complications of diabetes that can lead to blindness. Laser treatment has been the gold standard treatment for diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) for many years. Recently, the role of vascular endothelial growth factor (VEGF) has been established in the pathogenesis of DR, and the use of intravitreal anti-VEGF therapy has gained popularity for the management of DR. AREAS COVERED This review includes a brief overview of the efficacy and safety of currently available (bevacizumab, ranibizumab, and aflibercept) and potential future (brolucizumab, faricimab, and KSI-301) anti-VEGF agents in patients with DR based mainly on publicly available data from phase 1, 2 and 3 clinical trials. EXPERT OPINION Clinical trials investigating the efficacy of intravitreal bevacizumab, ranibizumab, and aflibercept injections demonstrated favorable functional and anatomical outcomes in patients with DME. Moreover, the use of these anti-VEGF agents showed a significant improvement in the severity of DR. Recent clinical research for future anti-VEGF molecules aims to provide higher target-protein binding affinity and prolonged therapeutic effect. Brolucizumab, faricimab, and KSI-301 are three novel anti-VEGF agents that demonstrate promising data for the management of DME and potentially DR.
Collapse
Affiliation(s)
- Gunay Uludag
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
| | - Muhammad Hassan
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
| | - Wataru Matsumiya
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
- Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Brandon Huy Pham
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
- Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, FL, USA
| | - Sophaktra Chea
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
| | | | - Hien Luong Doan
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
| | | | - Muhammad Sohail Halim
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
- Ocular Imaging Research and Reading Center, Sunnyvale, CA, USA
| | - Diana V Do
- Byers Eye Institute, Stanford University, Palo Alto, CA, USA
| | | |
Collapse
|